117: The Truth About Statins & Women’s Health: Can They Harm More Than They Help?

Bikman explains that CoQ10 is an electron carrier in the mitochondrial electron transport chain, crucial for ATP production. Statins deplete CoQ10 because it shares the same synthesis pathway as cholesterol. This depletion impairs mitochondrial function, leading to less ATP in muscle and beta cells, contributing to muscle pain and reduced insulin secretion. He cites a 2013 review noting a 10-20% drop in insulin secretion in high-dose users. Supplementing with 100-300 mg daily is the most evidence-based strategy to mitigate these effects. He also notes that while helpful, it won't fully reverse statin side effects, but it's the best available option.

Bikman explains that cholesterol is a 'molecule of life' necessary for cell membranes, hormones, and fetal development. Statins block its synthesis, and animal studies have long shown central nervous system and skeletal malformations. Although a recent human study of accidental first-trimester exposure did not find increased congenital anomalies, the animal evidence is so strong that the FDA recommends stopping statins months before conception and avoiding them throughout pregnancy and lactation. He emphasizes that this is a critical warning for women of childbearing age, and that the risk is not worth taking.

Ben Bikman walks through the evidence on statins for primary prevention in women. He notes that some meta-analyses suggest a relative risk reduction of about a third, but when you look at absolute numbers, the benefit is negligible. One systematic review found no significant impact on cardiovascular mortality. He mentions a 2022 meta-analysis that found a 15% reduction in all-cause mortality, but that still translates to tiny absolute changes. The Jupiter trial in women with elevated CRP showed some benefit but no mortality reduction. He emphasizes that the enthusiasm for statins in primary prevention for women is not supported by robust mortality data, and the benefits may be offset by harms like diabetes. He urges caution and a more nuanced view, especially since the absolute risk reduction is so small that it may not justify the side effects.

Bikman explains that ApoB measures the number of atherogenic particles, but in women, the association with heart disease is modest and fades with age. He contrasts this with metabolic markers: diabetes >10-fold, metabolic syndrome 6-fold, hypertension and obesity ~4.5-fold, LPIR 6.5-fold. He stresses that these differences are not subtle, and if we consider lipid markers meaningful, we cannot ignore the much stronger metabolic ones. He also notes that insulin resistance's effect holds even after adjusting for LDL and smoking. The takeaway: in women, lipids are weak, metabolic dysfunction is strong. He suggests that the hype around ApoB has far exceeded the evidence, especially for women.

Bikman details four mechanisms. First, a 2024 study showed statins reduce GLP-1 via unhealthy microbiome changes, exacerbating insulin resistance; if the microbiome was protected, GLP-1 and insulin sensitivity were preserved. Second, statins deplete CoQ10, reducing mitochondrial ATP production in beta cells, impairing insulin secretion by 10-20% in high-dose users. Third, statins trigger the NLRP3 inflammasome, promoting inflammation that damages beta cells and causes insulin resistance. Fourth, a 2023 paper found statins inhibit GLUT4 translocation, reducing glucose uptake into muscle and fat. He emphasizes that these effects compound, particularly in women, and could negate any cardiovascular benefit from LDL lowering. He credits Nick Norwitz for highlighting the GLP-1 paper.

Bikman explains that estrogen acts as a metabolic superhero, and its loss during menopause makes women more susceptible to insulin resistance. Statins appear to exacerbate this, with studies showing the near-50% increased diabetes risk specifically in post-menopausal women, not premenopausal. This is critical because post-menopausal women are the ones most targeted for statin therapy due to age-related cholesterol increases. He suggests that this risk, combined with the weak predictive power of LDL in women, should give clinicians pause. The effect persists even after adjusting for BMI and age.